A. Oza
Reproductive Medicine · 2003–2019
A researcher in the Science corpus: 14 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Reproductive Medicine — 105 citations into it
- Obstetrics and Gynecology — 14 citations into it
Whom A. Oza trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- J. Prat (in Reproductive Medicine)
Papers from A. Oza's perspective
Ordered by how strongly the researchers A. Oza trusts endorse each paper. Same corpus, a different order for every researcher.
- A candidate precursor to serous carcinoma that originates in the distal fallopian tube
- The Origin and Pathogenesis of Epithelial Ovarian Cancer- a Proposed Unifying Theory (American Journal of Surgical Pathology)
- Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer (Journal of Pathology)
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer (British Journal of Cancer)
- Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma (Science)
- Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA (Science Translational Medicine)
- THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
- Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers with Cancer Risk and Mortality (Journal of the American Medical Association (JAMA))
- Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival (Nature Medicine)
Their papers
- A phase 3 trial of bevacizumab in ovarian cancer. (2011) — 2,021 citations
- Epithelial ovarian cancer. (2019) — 762 citations
- Epithelial ovarian cancer: Evolution of management in the era of precision medicine (2019) — 1,318 citations
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer (2018) — 2,381 citations
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. (2017) — 1,515 citations
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. (2017) — 1,057 citations
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial (2017) — 1,446 citations
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. (2016) — 2,122 citations
- Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial (2015) — 794 citations
- Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. (2014) — 1,462 citations
- Rethinking Ovarian Cancer: Recommendations for Improving Outcomes (2011) — 1,276 citations
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. (2011) — 1,094 citations
- The statins as anticancer agents. (2003) — 634 citations
- Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. (2003) — 664 citations